

PROBLEM BEHAVIORS RESOURCES

Patient-Provider Communication

- [Example of Office-Based Opioid Treatment Policies](#) [PDF] Provides an example of office-based policies that might be used in your provider's practice (*Source: Clinical Tools, Inc.*)
- [Hablando con su médico \(Talking to Your Doctor \(en Español\)\)](#) [PDF] Discusses the importance of honesty from both the patient and the doctor when talking about drug use and treatment (*Source: Clinical Tools, Inc.*)
- [Sample Treatment Agreement/Contract \(TIP 40 Appendix H\)](#) Patient contract that can be used to set expectations and guidelines before beginning buprenorphine treatment (*Source: SAMHSA*)
- [Talking to Your Doctor](#) [PDF] Discusses the importance of honesty from both the patient and the provider when talking about drug use and treatment (*Source: Clinical Tools, Inc.*)

Locating Treatment

- [Behavioral Health Treatment Services Locator](#) The behavioral health treatment services locator is an online source of information for persons seeking treatment facilities in the United States or U.S. Territories for substance abuse/addiction and/or mental health problems (*Source: SAMHSA*)
- [Opioid Treatment Program Directory](#) This directory allows you to find opioid treatment programs by state (*Source: SAMHSA*)
- [SAMHSA's Buprenorphine Physician and Treatment Program Locator](#) A directory of treatment programs and physicians authorized to treat patients with buprenorphine (*Source: SAMHSA*)

Additional Resources

- [A Closer Look at State Prescription Monitoring Programs \(DEA FAQ's\)](#) These FAQs address common questions regarding prescription drug monitoring programs (*Source: DOJ/DEA*)
- [Adherence, Diversion and Misuse of Sublingual Buprenorphine](#) [PDF] Discusses types of aberrant behavior associated with buprenorphine and steps that can be taken to reduce the risk of abuse and diversion (*Source: PCSS*)
- [Appropriate Use Checklist](#) [PDF] Reminder of the safe use conditions and monitoring requirements for prescribing buprenorphine-containing transmucosal products for opioid dependence (*Source: BTOD-REMS*)
- [Clinical Laboratory Improvement Amendments \(CLIA\) - Currently Waived Analytes](#) A list of currently waived analyses that are used in laboratory test systems, which provides the analyte name as well as a link to the waived test system (*Source: FDA*)
- [Suboxone Sublingual Film \(CIII\)](#) [PDF] Patient information sheet on buprenorphine plus naloxone sublingual film [commercial site] (*Source: Indivior*)
- [Prescription Drug Monitoring Program Training and Technical Assistance Center](#) Provides

- support and resources for multiple stakeholders regarding PDMPs (*Source: PDMP-TTAC*)
- [SAMHSA TIP 43, Chapter 9: Drug Testing as a Tool](#) Discusses the use of drug testing as a means of monitoring patient progress and treatment efficacy (*Source: SAMHSA*)